Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
doxorubicin-HPMA conjugate
- Development stage
- Phase 2
- Lead developer
- Pfizer
- Modality
- Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
A polymer-drug conjugate consisting of doxorubicin bound to N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer through oligopeptide spacers. This conjugate enhances the permeability and retention of doxorubicin within tumor vasculature (EPR effect) while reducing systemic toxicity. The drug is released from the polymer through enzymatic degradation of the peptide linker by lysosomal enzymes such as cathepsin B, allowing for targeted delivery to cancer cells.
- Other names
- Doxorubicin-HPMA-glucose conjugate
02
Targets
TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on doxorubicin-HPMA conjugate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on doxorubicin-HPMA conjugate.